web analytics

Digestix; RCC-33; the Run on Cannabics Pharmaceuticals Inc (OTCMKTS: CNBX)

0

Cannabics Pharmaceuticals Inc (OTCMKTS: CNBX) saw a big move last week after the Company filed an 8k and reported it has established a subsidiary, Digestix Bioscience Inc., a company dedicated to the development of medical devices and pharmaceutical compositions for the treatment of precancerous and early stage neoplastic local tumors. The new company’s initial focus is in developing a medical device and a pharmaceutical composition with inhibitory effects for preventing recurrence of certain adenomatous colorectal polyps.

CNBX lead product is RCC-33, an oral capsule for the treatment of colorectal cancer. CNBX is also developing Cannabics SR; a lipid-based capsule containing a standardized formulation of cannabinoids that it is developing as a product candidate for the treatment of cancer anorexia-cachexia syndrome. CNBX is also developing Cannabics CDx, a drug sensitivity test designed to provide innovative decision support to healthcare providers interested in personalizing cannabinoid-based cancer therapies. Penny stock speculators are watching CNBX closely here as the stock has a history of big moves running to $2.80 per share in late 2016.

Cannabics Pharmaceuticals Inc (OTCMKTS: CNBX) is a U.S. public company and a global leader in the development of cancer related cannabinoid-based therapeutic formulations and medicines. The Company’s R&D is based in Israel, where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and cancer. The Company’s core technology is a continuously evolving bioinformatics platform that utilizes high-throughput screening technology, advanced data analytics, and proprietary methodologies to rapidly examine the physiologic effect of multiple cannabinoid compounds on tumor cells. This technology enables us to screen thousands of cannabinoid combinations weekly, generating multiple datasets on the anti-tumor properties of different cannabinoid formulations and ratios. We conduct a broad range of preclinical research on cannabinoids through our bioinformatics platform, which informs the development of our product candidates.

CNBX lead product candidate is RCC-33, an oral capsule for the treatment of colorectal cancer (“CRC”). RCC-33 contains high concentrations of the cannabinoids CBDV and CBGA, which have demonstrated complex synergistic anti-tumor activity in its in vitro studies, with minimal psychoactive effects. We are currently in the early planning stage of a clinical development pathway for RCC-33. We plan to conduct further preclinical studies to establish the safety and efficacy of RCC-33 in an in vivo murine model of colorectal cancer. Subject to the results of our preclinical studies, we intend to proceed to phase 1/2a clinical study in the second half of 2022.

CNBX is also developing Cannabics SR; a lipid-based capsule containing a standardized formulation of cannabinoids that it is developing as a product candidate for the treatment of cancer anorexia-cachexia syndrome (“CACS”). With a rapid onset of action and sustained effects for up to 6-8 hours, we believe that the convenience of once or twice daily oral dosing of Cannabics SR may improve quality of life and increase patient compliance with treatment regimens, leading to better health outcomes. A two-year pilot study of Cannabics SR led by Dr. Gil Bar-Sela of the Rambam Hospital Health Care Campus, Division of Oncology, in Haifa, Israel, demonstrated a clinically significant weight increase in CACS patients treated with Cannabics SR capsules.

To Find out the inside Scoop on CNBX Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

CNBX

Another product candidate CNBX is developing is Cannabics CDx, a drug sensitivity test designed to provide innovative decision support to healthcare providers interested in personalizing cannabinoid-based cancer therapies. Cannabics CDx applies data analytics and high-content drug sensitivity screening integrated with our proprietary database to measure the effectiveness of cannabinoid compounds on a patient’s biopsy, suggest preferred alternatives, and alert healthcare providers to cannabinoids that may be contraindicated.

Earlier this month CNBX reported it has completed a pre-clinical study using its proprietary and novel RCC-33 formulation on human biopsies, obtained under a Helsinki Committee approved protocol. The results show an antitumor synergistic effect of the active compounds, thus confirming the company’ previously obtained data on the antitumor properties of the drug candidate when screened on colorectal cell lines. A Colon Biopsy Sample in Preparation for its Cannabics Drug Sensitivity Test.

On November 16 CNBX announced it has established a subsidiary, Digestix Bioscience Inc., a company dedicated to the development of medical devices and pharmaceutical compositions for the treatment of precancerous and early stage neoplastic local tumors. The new company’s initial focus is in developing a medical device and a pharmaceutical composition with inhibitory effects for preventing recurrence of certain adenomatous colorectal polyps.

Adenomatous colorectal polyps are found in approximately 25-30% of colonoscopies performed on men and women over the age of 50, and according to iData Research, approximately 19 million colonoscopies are performed in the US annually. The new company is founded by Professor Eitan Scapa, Dr. Erez Scapa, Gabriel Yariv and Cannabics Pharmaceuticals as a majority shareholder. Gabriel Yariv, who currently serves as Director and COO of Cannabics Pharmaceuticals, will also serve as interim Chairman and CEO of Digestix Bioscience during initial setup. Digestix Bioscience will be led by Prof. Eitan Scapa; a Full Professor of Medicine at Tel Aviv University specialising in gastroenterology and liver diseases.

Eyal Barad, Cannabics Pharmaceuticals’ CEO said: “The establishment of Digestix Bioscience is a great example of how Cannabics can stay focused on its core activities while leveraging its knowhow and expertise to establish new ventures and partnerships in order to tap adjacent markets such as that of medical devices and pre-cancerous and early stage local tumors in this case”.

We have a Monster Pick Coming. Subscribe Right Now!

Currently on the move after a long period of little activity CNBX is an exciting story developing in small caps; focused on being the leader in personalized cannabinoid medicine focused on cancer and its side effects, with a team of scientists diligently working to develop and expand their intellectual property portfolio. CNBX lead product is RCC-33, an oral capsule for the treatment of colorectal cancer. CNBX is also developing Cannabics SR; a lipid-based capsule containing a standardized formulation of cannabinoids that it is developing as a product candidate for the treatment of cancer anorexia-cachexia syndrome. CNBX is also developing Cannabics CDx, a drug sensitivity test designed to provide innovative decision support to healthcare providers interested in personalizing cannabinoid-based cancer therapies. Penny stock speculators are watching CNBX closely here as the stock has a history of big moves running to $2.80 per share in late 2016. We will be updating on CNBX when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with CNBX.

Sign Up now for our 100% FREE Penny Stock Newsletter

Disclosure: we hold no position in CNBX either long or short and we have not been compensated for this article.

Share.

Leave A Reply

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.